- Home >
- Clinicals Trials >
- ENCO-BRAF (IFCT-1904)
Retour à la liste des essais cliniquesLung cancer
ENCO-BRAF (IFCT-1904)
A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
- Ouvert à Paris depuis le : 02/03/2022
- Public cible : Adult
- Phase : Phase II
Description de l'essai
Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Url of the trial